COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer (COGNITION)
COGNITION: Comprehensive Assessment of Clinical Features, Genomics and Further Molecular Markers to Identify Patients with Early Breast Cancer for Enrolment on Marker Driven Trials (Molecular Diagnostic Platform)
Sponsor: German Cancer Research Center
A observational or N/A phase clinical study on Early-Stage Breast Cancer and Neoadjuvant Therapy, this trial is actively recruiting participants. The trial is conducted by German Cancer Research Center and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Recruiting
-
Apr 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Dec 2023 — Jul 2024 [monthly]
Recruiting
▶ Show 1 earlier version
-
Jul 2023 — Dec 2023 [monthly]
Recruiting
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- German Cancer Research Center
- German Federal Ministry of Education and Research
- University Hospital Heidelberg
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Augsburg, Germany , Berlin, Germany , Cologne, Germany , Dresden, Germany , Erlangen, Germany , Essen, Germany , Heidelberg, Germany , Regensburg, Germany , Stuttgart, Germany , Tübingen, Germany and 2 more locations